RT Journal Article
SR Electronic
T1 Effects of estradiol on biological age measured using the glycan age index
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.25.20138503
DO 10.1101/2020.06.25.20138503
A1 Jurić, Julija
A1 Kohrt, Wendy M.
A1 Kifer, Domagoj
A1 Pezer, Marija
A1 Nigrovic, Peter A.
A1 Lauc, Gordan
YR 2020
UL http://medrxiv.org/content/early/2020/06/29/2020.06.25.20138503.abstract
AB Glycan age is a recently developed biomarker based on glycans attached to immunoglobulin G (IgG). In large population cohorts glycan age associates well with lifestyle and disease-risk biomarkers, while some studies suggested that change in glycans precede development of several age-associated diseases. In this study we evaluated effects of estrogen on the glycan age. Gonadal hormones were suppressed in 36 healthy young women by gonadotropin releasing hormone agonist therapy for 6 months. In 15 of them estradiol was supplemented, while 21 received placebo resulting in very low estrogen levels during intervention. IgG was isolated from plasma samples before intervention, after 6 months of intervention and after subsequent 4-month recovery. In the placebo group the removal of gonadal hormones resulted in median increase of glycan age for 9.1 years (IQR 6.8 – 11.5 years, p = 3.73×10−8), which was completely prevented by transdermal estradiol supplementation. After the recovery period glycan age returned to baseline values also in the placebo group. These results suggest that IgG glycans and consequently also the glycan age are under strong influence of gonadal hormones and that hormone replacement therapy can prevent the increase of glycan age that occurs in the perimenopausal period.Competing Interest StatementG. Lauc is the founder and owner of Genos Ltd, a private research organization that specializes in high-throughput glycomic analyses and has several patents in this field. J. Jurić, F. Vučković and M. Pezer are employees of Genos Ltd. G. Lauc is also co-founder of GlycanAge Ltd and is listed as an inventor on patents EP3011335B1 and US9910046B2 that protect the use of glycan age to predict biological age. All other authors declare no conflicts of interest.Clinical TrialThe intervention study was registered on ClinicalTrials.gov (NCT00687739) on May 28, 2008. Glycan analysis performed for this study was not available in 2008 and was not originally planned. It was performedd in 2020 in leftover plasma samples from the trial.Funding StatementGlycosylation analysis was performed in Genos Glycoscience Research Laboratory and partly supported by the European Structural and Investment Funds IRI grant (#KK.01.2.1.01.0003), Centre of Competence in Molecular Diagnostics (#KK.01.2.2.03.0006) and Croatian National Centre of Research Excellence in Personalized Healthcare grant (#KK.01.1.1.01.0010). PAN was supported by the US National Institute of Arthritis and Musculoskeletal and Skin Diseases grant P30AR070253.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted at the University of Colorado Anschutz Medical Campus (CU-AMC). Procedures followed were in accordance with the ethical standards of and approved by the Colorado Multiple Institutional Review Board (COMIRB) and the Scientific Advisory and Review Committee at the University of Colorado Anschutz Medical Campus (CU-AMC). The study was registered on ClinicalTrials.gov (NCT00687739) on May 28, 2008.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available upon reasonable request